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Abstract
Background: The clinical management of leprosy Type 1 (T1R) and Type 2 (T2R) reactions pose challenges
mainly because they can cause severe nerve injury and disability. No laboratory test or marker is available for the
diagnosis or prognosis of leprosy reactions. This study simultaneously screened plasma factors to identify
circulating biomarkers associated with leprosy T1R and T2R among patients recruited in Goiania, Central Brazil.
Methods: A nested case-control study evaluated T1R (n = 10) and TR2 (n = 10) compared to leprosy patients
without reactions (n = 29), matched by sex and age-group (+/- 5 years) and histopathological classification.
Multiplex bead based technique provided profiles of 27 plasma factors including 16 pro inflammatory cytokines:
tumor necrosis factor-α (TNF-α), Interferon-γ (IFN-γ), interleukin (IL)- IL12p70, IL2, IL17, IL1 β, IL6, IL15, IL5,
IL8, macrophage inflammatory protein (MIP)-1 alpha (MIP1α), 1 beta (MIP1β), regulated upon activation normal
T-cell expressed and secreted (RANTES), monocyte chemoattractrant protein 1 (MCP1), CC-chemokine 11
(CCL11/Eotaxin), CXC-chemokine 10 (CXCL10/IP10); 4 anti inflammatory interleukins: IL4, IL10, IL13, IL1Rα
and 7 growth factors: IL7, IL9, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony
stimulating factor (GM-CSF), platelet-derived growth factor BB (PDGF BB), basic fibroblast growth factor (bFGF),
vascular endothelial growth factor (VEGF).
Results: Elevations of plasma CXCL10 (P = 0.004) and IL6 (p = 0.013) were observed in T1R patients compared
to controls without reaction. IL6 (p = 0.05), IL7 (p = 0.039), and PDGF-BB (p = 0.041) were elevated in T2R.
RANTES and GMCSF were excluded due to values above and below detection limit respectively in all samples.
Conclusion: Potential biomarkers of T1R identified were CXCL10 and IL6 whereas IL7, PDGF-BB and IL6, may
be laboratory markers of TR2. Additional studies on these biomarkers may help understand the
immunopathologic mechanisms of leprosy reactions and indicate their usefulness for the diagnosis and for the
clinical management of these events.
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Background
Leprosy reactions are major causes of hospitalization and
disability of patients with leprosy, a chronic granuloma-
tous disease of the skin and peripheral nerves caused by
the Mycobacterium leprae. These are understood to be con-
sequences of the dynamic nature of the immune response
to M. leprae, and they may occur before diagnosis, during
treatment or after multidrug therapy (MDT). Leprosy
"Type 1" reactions (T1R), also described as "reversal" reac-
tions, occur in 30–40% of borderline patients with cellu-
lar immune responses to M. leprae [1]. T1R usually
develops abruptly as exacerbations of pre-existing skin
and nerve lesions. Treatment with corticosteroids allevi-
ates symptoms, but often requires many weeks or months
of moderate to high doses.
"Type 2" reactions (T2R), also known as erythema nodosum
leprosum (ENL), occur only in lepromatous (LL) and bor-
derline lepromatous (BL) patients with a high bacterial
load and little or no cellular immunity to M. leprae [1].
T2R develop abruptly, with crops of red, tender nodules
on various parts of the body, and histological evidence of
acute inflammation. The natural course of T2R is typically
10 – 14 days, but without treatment severe tissue damage,
including nerves, often results. Corticosteroids and thalid-
omide reduce the inflammation in T2R, but many
patients have multiple, recurrent episodes.
Neuritis and cutaneous inflammation are prominent
symptoms of both types of reaction, but the systemic
nature of these reactions is evident from the patterns of
malaise, fever, and inflammation in other tissues that are
characteristic of both T1R and especially T2R reactions. In
leprosy reactions, peripheral immunological and inflam-
matory mechanisms are undoubtedly important, but
enhanced central immunological reactivity in spleen and
lymph nodes may contribute to the overall illness. In
human studies, plasma provides an appropriate sample of
the soluble mediators produced by central lymphoid
organs.
Cytokines play important roles in both protection and
immunopathology of leprosy and are considered impor-
tant components of leprosy reactions: reviewed in [2].
T1R have been characterized by in situ Th1 type immunity
with spontaneous increase in cell mediated immunity
with infiltration of IFNγ and TNFα, secreting CD4+T cells
in skin lesions and nerves. The T2R is a systemic inflam-
matory response characterized by neutrophil infiltration,
activation of complement, extra-vascular immune com-
plexes and high levels of TNFα in tissue lesions and in the
circulation [3-5]. The presence of M. leprae DNA detected
by PCR in skin lesions has been demonstrated to be a
molecular marker of T1R among single skin lesion PB lep-
rosy [6]. Despite evidences of immunological and molec-
ular mediators of leprosy reactions, no individual marker
or combination of markers has been sufficiently associ-
ated with wither reaction to enable its use as a laboratory
test for the diagnosis or management of T1R or T2R.
The goal of this study was to screen potential plasma
markers in Type 1 and Type 2 leprosy reactions. Profiles of
27 markers including 16 circulating pro inflammatory, 4
anti inflammatory cytokines and 7 growth factors were
compared among T1R and T2R patients and leprosy
patients without reaction (matched for age, sex, and lep-
rosy type).
Methods
Patients
This study was designed as a nested case-control study
within a cohort of 349 newly detected untreated leprosy
patients recruited between February 2004 and October
2005 at a main outpatient clinic in Central Brazil (Refer-
ence Center for Diagnosis and Treatment, Goiania city).
Eligibility criteria were: newly diagnosed untreated lep-
rosy patients. Leprosy patients living outside the study
area or patients not willing to come for follow up were
excluded. At baseline, patients were given complete der-
matological and neurological evaluations by a dermatolo-
gist and a physiotherapist with expertise in leprosy
diagnosis. Slit skin smears and skin lesion biopsies were
collected at baseline and histhopathological readings
were classified according to Ridley-Jopling criteria [7]. All
patients received the standard WHO MDT regimen for PB
or MB disease and patients were followed-up during MDT
to monitor any episode of leprosy reaction. Leprosy reac-
tions were treated according to the guidelines from the
Brazilian Leprosy Control Program.
In this study, T1R cases were selected from untreated lep-
rosy patients clinically diagnosed with T1R (n = 10) the
time of their initial diagnosis. These patients had severely
indurated and erythematous lesions at the site of previ-
ously indolent macules, according to the medical history.
T2R cases (n = 10) were selected among patients who had
the T2R at diagnosis (n = 4) or during follow up (n = 6).
The following case definitions were employed: T1R was
defined as an acute clinical manifestation, usually charac-
terized by the exacerbation of pre-existing lesions, the
appearance of new lesions with or without neuritis. T2R
was characterized by the sudden appearance of tender ery-
thematous skin nodules mainly accompanied by fever
and other systemic symptoms such as joint pain, bone
tenderness, neuritis, edema, malaise, anorexia with or
without lymphadenopathy. Controls were selected
among leprosy patients with the same histopathological
classification as the reaction patients but did not have
reaction at the time of initial diagnosis or during follow-
up. These controls were also matched by sex and age-BMC Infectious Diseases 2009, 9:75 http://www.biomedcentral.com/1471-2334/9/75
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group (+/- 5 years). Ten controls were found suitable for
TR1 and 9 controls for TR2.
Data Collection and Ethical Issues
A standardized Case Report Form (CRF) was applied to all
patients to collect data on age, sex, duration of symptoms,
clinical characteristics, neurological impairment, onset of
reaction and final classification. This study was approved
by the institutional review board and all patients gave
written, informed consent.
Blood Collection and Cytokine Analysis
Blood was collected in EDTA, centrifuged immediately,
and plasma aliquots were stored at -80°C prior to assay.
Cytokine Array System
This study employed a commercially available premixed
human cytokine 27-plex panel of cytokines (Bio-Plex
Cytokine reagent kit, BIO RAD Laboratories, Hercules,
CA, USA). This system consists of multiplex beads and
detection antibodies designed to quantitate, in pg/ml,
multiple cytokines in plasma samples. This study
employed the premixed 27-plex panel of human
cytokines. For data analysis the 27 cytokines were strati-
fied into 3 functional categories: A. Pro-inflammatory
cytokines- TNFα, IFNγ, IL12, IL2, IL17, IL1 β, IL6, IL15,
IL5, IL8, CXCL10, MIP1α, MIP1β, RANTES, MCP1 and
CCL11; B. Anti- inflammatory cytokines- IL4, IL10, IL13
and IL1Rα; C. Growth Factors- IL7, IL9, GMCSF, GCSF,
PDGF-BB, FGF-Bas and VEGF.
EDTA plasma samples stored at -80°C were thawed, cen-
trifuged at 1,000 × g at 4°C for 10 min, supernatants were
filtered (sterile 0.22 um Millipore filters) and used imme-
diately. All samples were tested in duplicate at 1/3 dilu-
tion in species specific Bio-plex sample diluent, and blank
values (background) were subtracted from all readings.
Premixed lyophilized cytokine standards, premixed anti
cytokine conjugated beads, detection antibodies and
Streptavidin-PE were prepared according to manufacturer
instructions. All assays were read on the Luminex 100
Instrument (Austin, Texas) and data analysis performed
with the Bio-Plex-Manager software which includes deter-
mination of assay precision and determination of good-
ness of fit of the regression algorithm.
Statistical Analysis
The concentration of individual cytokines in pg/ml in
each patient was used for data analysis. Descriptive statis-
tics were applied to the patient's characteristics. Explora-
tory data analysis, including box-plot, medians and
standard deviation were calculated for the concentration
of each cytokine and results were stratified by groups of
cases (T1R and T2R) and compared to plasma concentra-
tions obtained in their respective control groups. Statisti-
cal significance was assessed by Kruskall-Wallis one way
analysis of variance for comparison of multiple groups
and Mann-Whitney for comparison between two groups.
P values < 0.05 were considered statistical significant
results.
Results
Patients' characteristics
The main baseline clinical characteristics of the 39 leprosy
patients tested during T1R (n = 10) and controls (n = 10)
or T2R (n = 10) and controls (n = 9) are shown in Table 1.
Table 1: Baseline clinical characteristics of patients with leprosy reactions and controls without reaction
Characteristics T1R1 Controls2 T2R3 Controls4
Patients n (%) 10 10 10 9
Sex
men 8 (80.0) 8 (80.0) 8 (80.0) 7 (77.8)
women 2 (20.0) 2 (20.0) 2 (20.0) 2 (20.0)
Age (median) 42.9 41.4 38.9 43.3
(min-max) (26–60) (26–59) (17–69) (13–68)
Classification
BT 10 10 - -
LL - - 10 9
Baciloscopic Index
(median) 0 0 3.25 2.75
(min-max) (-) (-) (2.5–5.0) (2.5–5.0)
Reaction at diagnosis 10 (100.0) - 04 (40.0) -
Duration of symptoms prior to diagnosis (days)
(median) 50 - 15 -
(min-max) (3–120) (3–60)
1 Type 1 Reaction
2 Paucibacillary leprosy patients without reaction
3 Type 2 Reaction
4 Multibacillary leprosy patients without reactionBMC Infectious Diseases 2009, 9:75 http://www.biomedcentral.com/1471-2334/9/75
Page 4 of 8
(page number not for citation purposes)
Adult males around 40 years of age predominated in all
groups. Patients with T1R and controls were classified by
clinical and histopathological criteria as BT and none had
acid-fast bacilli in skin smears (BI = 0). Patients with T2R
and controls had LL disease; all had acid-fast bacilli in
skin smears. For patients diagnosed during a reactional
episode (10/10 T1R and 4/10 T2R cases), a wide variation
in the duration of symptoms prior to diagnosis was
reported: median of 50 days for T1R and 15 days for T2R.
No clinical differences were identified between patients
who had T2R on diagnosis compared to those who devel-
oped the reaction after starting MDT. None of the leprosy
patients included in the study had neuritis. Prednisolone
was the treatment of choice for all T1R patients. T2R
patients were treated with steroid (n = 6) or thalidomide
(n = 3) or steroid and thalidomide combination (n = 1).
Cytokine Analysis
Regardless of the study group and cytokine classification,
a wide variation was observed in the plasma concentra-
tion of cytokines tested (data not shown). Among pro-
inflammatory cytokines, IL-6 levels ranged from 31.81 to
724 pg/ml, median = 103.20 (SD = 129.42). For anti-
inflammatory cytokines IL1Rα values ranged from 44.24
pg/ml to 2642 pg/ml, median = 179.52 (SD = 529.63).
Among growth factors the widest variation was observed
fro PDGF BB concentration (median = 4264.47; SD =
3131.78). Two out of 27 cytokines tested, RANTES and
GMCSF were excluded from the analysis because their val-
ues were above and below detection limit respectively.
High RANTES levels were probably artifacts, since plate-
lets had not been removed from the plasma prior to freez-
ing.
Pro-inflammatory cytokines
Box plots distributions indicate differences in median
plasma concentrations for all of the 15 inflammatory
cytokines stratified by T1R cases and controls (Figure 1A)
and T2R and controls (Figure 2A). The difference of
CXCL10 median plasma concentration among T1R and
their matched controls was highly significant (p = 0.004)
(Fig 1A). IL6 also showed statistically significant differ-
ences between T1R patients and matched controls (p =
0.013) (Fig. 1A), while the difference for T2R patients and
matched controls did not reach statistical significance (P
= 0.05) (Fig. 2A). The differences between medians of
CCL11 concentrations among T2R (363.6 pg/ml) and
controls (218.6 pg/ml) were notable but not statistically
significant (p = 0.06) (Fig. 2A).
The differences between median values of TNFα, IFN γ,
IL1  β, IL12, IL15, IL2, IL5, IL8, MIP1α, MIP1β, IL17,
MCP1 were not statistically different (p > 0.05) for non-
reactional T1R-controls and T2R-controls (Figures 1A and
2A). For TNFα the median for T2R cases was 171.8 pg/ml
and for the control group without reaction the median
was 67.7 pg/ml (p = 0.297). The medians of IFNγ for T2R
and controls were 358.0 pg/ml and 315.4 pg/ml respec-
tively (Fig. 2A). No associations were observed between
cytokine and chemokine concentrations and the duration
of reaction symptoms (data not shown), although the
sample may be too small to reliably determine this.
Anti-Inflammatory cytokines
The difference between median values of IL10 plasma
concentrations among T2R patients (median = 56.9 pg/
ml) and controls (median = 39.4 pg/ml) was marginally
significant (p = 0.07) (Figure 2B). Regarding IL4, IL13 and
IL1Rα there was no statistically significant difference in
the plasma concentration medians between type 1 and
type 2 reactional groups and their respective control lep-
rosy groups without reaction (Figures 1B, 2B).
Growth Factors
Regarding IL7, IL9, GMCSF, GCSF, PDGF-BB, FGF-Bas
and VEGF, no difference was observed among T1R and
controls (Figure 1C). For T2R the difference of medians
between cases and controls was statistically significant for
IL-7 (p = 0.039) and PDGF-BB (p = 0.041) and marginally
significant for VEGF (p = 0.06) (Figure 2C).
Discussion
This is the first description of the plasma profiles of a rea-
sonably large panel of pro-inflammatory, anti-inflamma-
tory and growth factors assessed simultaneously by
multiplex technique among T1R and T2R patients com-
pared to well-matched leprosy patients without reaction.
The results indicate that CXCL10 is a promising biomar-
ker of T1R, at least in BT patients, since those with T1R
had a significant elevation of circulating CXCL10. This is
the first observation of high levels of circulating CXCL10
in leprosy.
CXCL10, one of the IFN-γ inducible chemokines that
recruits effector Th1 type cells to delayed type hypersensi-
tivity sites, has been previously identified in tuberculoid
lesions [8]. Although our study was not designed to inves-
tigate mechanisms, the higher levels of CXCL10 detected
in T1R suggest its involvement in the T1R immunopathol-
ogy probably by attracting Th1 type cells to the reactional
inflammatory sites in the skin, (reviewed in [1]).
CXCL10 has been associated with Th1 type responses in
several clinical systems recruiting CXCR3+ effector lym-
phocytes from the peripheral blood into lupus erythema-
tosus skin lesions [9], and into inflammatory lesions of
the central nervous system [10]. CXCL10 has been pro-
posed to be an immune marker of disease progression in
HIV and tuberculosis patients [11] and was increased in
sarcoidosis patients' serum. High levels of CXCL10 wereBMC Infectious Diseases 2009, 9:75 http://www.biomedcentral.com/1471-2334/9/75
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Distribution of cytokines among Type 1 reaction leprosy patients (traced boxes) and controls without reaction (white boxes) Figure 1
Distribution of cytokines among Type 1 reaction leprosy patients (traced boxes) and controls without reaction 
(white boxes). (A) Pro inflammatory Cytokines, CXCL10 and IL-6 median values were statistically higher for TR1 than con-
trols (B) Anti Inflammatory cytokines (C) Growth Factors. Boxes encompass 25th and 75th percentiles of each cytokine distri-
bution. Black lines within boxes refer to the median values.BMC Infectious Diseases 2009, 9:75 http://www.biomedcentral.com/1471-2334/9/75
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Distribution of cytokines among Type 2 reaction leprosy patients (traced boxes) and controls without reaction (white boxes) Figure 2
Distribution of cytokines among Type 2 reaction leprosy patients (traced boxes) and controls without reaction 
(white boxes). (A) Pro inflammatory Cytokines (B) Anti Inflammatory cytokines (C) Growth Factors, IL-7 and PDGF-BB 
median values were statistically higher among cases than in the control group. Boxes encompass 25th and 75th percentiles of 
each cytokine distribution. Black lines within boxes refer to the median values.BMC Infectious Diseases 2009, 9:75 http://www.biomedcentral.com/1471-2334/9/75
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found in the cerebrospinal fluid of multiple sclerosis
patients' during intense inflammatory process [12-14].
CXCL10 has not been associated with inflammation of
peripheral nerves but its possible involvement in the neu-
ropathy associated with T1R deserves further study.
Another promising systemic marker of T1R is the inflam-
matory cytokine IL6, which promotes cell mediated
immune reactions notably by stimulating IL17, and by
inhibiting regulatory T cells. IL6 stimulates the synthesis
of acute-phase proteins and is elevated in stressful inflam-
matory or infectious conditions [15]. Increased serum IL-
6 has recently also been reported in T2R, and in leproma-
tous versus tuberculoid disease [16].
Greater IL7 was observed in LL patients with T2R com-
pared to non-reacting LL patients. We did not observe
greater circulating levels of IL7 in tuberculoid patients
compared to lepromatous ones, unlike earlier skin biopsy
studies which found greater IL7 mRNA expression in
tuberculoid lesions versus lepromatous ones, and T2R
lesions showed the weakest IL7 expression [17]. Different
immunological activity in the central lymphoid system
(reflected in the circulation) versus sites of inflammation
in tissue may explain this. IL7 is a key regulator of B cell
development and proliferation [18], and is essential for
the survival of naïve and memory T cells, especially CD4
memory cells [19]. Elevated circulating levels of IL7 in
T2R thus support a role for both B-cell and T-cell medi-
ated mechanisms in this reaction.
CCL11 previously named eotaxin, a chemokine induced
by interferon-γ and produced by monocytes, was identi-
fied as a potential plasma marker of T2R. Recently, greater
plasma concentrations of CCL11 have been shown in Bra-
zilian MB leprosy patients, when compared to non
infected individuals [20]. CCL11 is a potent chemo
attractant for eosinophils and probably other cell types
such as Th2 lymphocytes, to inflammatory sites [21,22]. It
is possible that CCL11 participates in attracting inflam-
matory cells to T2R sites.
Anti-inflammatory cytokines down-modulate inflamma-
tory responses and reduce immunopathology. Among
anti-inflammatory cytokines (IL4, IL10, IL13 and IL1RA)
only IL10 showed marginally significant difference for
T2R. This finding is in agreement with previous studies in
plasma, IL10 mRNA in T2R skin lesions, and after in vitro
stimulation of peripheral blood mononuclear cells of T2R
patients [4,23-26].
Significant differences were observed between T2R and
controls for the growth factors PDFG-BB and VEGF, both
of them known to promote angiogenesis. This is an inter-
esting finding as T2R are often associated with vasculitis
[27,28].
While several studies indicate an important role for TNFα
in reactional states, especially T2R [29-32], this finding
has not always been confirmed [33,34]. Our results indi-
cated that TNFα levels among reactional patients were not
statistically different from the non-reactional patients.
Previous studies with T2R patients have reported undetec-
table or low levels of TNFα [35] or have not found
increased circulating TNFα [31,36]. This study evaluated
levels of TNFα in plasma and used a multiplex bead assay,
unlike most prior work that has used ELISA technology to
assess cytokines in serum.
IL17, produced by pro-inflammatory TH17 lineage of
effector CD4+ T helper lymphocytes, induces the produc-
tion of chemokines and antimicrobial peptides by tissue
cells leading to the recruitment of neutrophils and inflam-
mation [37]. In this study IL17 did not show significant
difference between reactional and non reactional leprosy
patients.
Conclusion
This survey of circulating cytokines has identified eleva-
tions in CXCL10 and IL6 as promising markers for leprosy
T1R. These findings are consistent with T1R cell-mediated
immunolopathologic basis. IL7 and PDGF-BB represent
potential markers of T2R. Additional studies may deter-
mine the sensitivity and specificity of these cytokines as
leprosy reactions markers. The identification of T1R and
T2R markers can contribute to their clinical diagnosis and
for monitoring their resolution during treatment. In addi-
tion, these findings may provide new clues to the patho-
genesis of leprosy reactions.
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